白三烯受体拮抗剂在哮喘患者中抗炎、改善免疫功能的效果分析

Effect of leukotriene receptor antagonist on anti-inflammation and improving immune function in asthmatic patients

目的探讨白三烯受体拮抗剂(孟鲁司特)在哮喘患者中抗炎以及改善免疫功能的效果。方法 80例哮喘患者,随机分为对照组(30例)和观察组(50例)。对照组患者采用糖皮质激素治疗,观察组在对照组基础上给予孟鲁司特治疗,比较两组患者治疗前后的炎性因子水平及免疫功能指标。结果治疗前两组患者的C反应蛋白(CRP)、白细胞介素-6(IL-6)水平比较差异均无统计学意义(P>0.05)。治疗后观察组CRP、IL-6水平为(6.32±2.22)mg/L、(67.43±12.29)ng/L,对照组为(10.20±3.06)mg/L、(89.02±15.47)ng/L;治疗后两组患者的CRP、IL-6水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗前两组患者CD4+、CD8+比较差异无统计学意义(P>0.05);治疗后两组患者CD8+低于治疗前,CD4+高于治疗前,且观察组CD8+低于对照组,CD4+高于对照组,差异均有统计学意义(P<0.05)。两组均未见明显不良反应。结论孟鲁司特能够提高哮喘的治疗效果,其作用机制可能与其降低患者的炎性因子水平以及提高免疫功能有关。

Objective To discuss the effect of leukotriene receptor antagonist（Montelukast） on antiinflammation and improving immune function in asthmatic patients. Methods A total of 80 asthmatic patients were randomly divided into control group（30 cases） and observation group（50 cases）. The control group was treated with glucocorticoids, and the observation group was treated with Montelukast on the basis of the control group. Comparison were made on levels of inflammatory factors and immune function indexes before and after treatment in two groups. Results Before treatment, both groups had no statistically significant difference in levels of C reactive protein（CRP） and interleukin-6（IL-6）（P〉0.05）. After treatment, the observation group had CRP and IL-6 level as（6.32±2.22） mg/L and（67.43±12.29） ng/L, which were（10.20±3.06） mg/L and（89.02±15.47） ng/L in the control group. After treatment, both groups had lower CRP and IL-6 level than before treatment, and the observation group was lower than the control group. Their difference was statistically significant（P〈0.05）. Before treatment, both groups had no statistically significant difference in CD4＋ and CD8＋（P〉0.05）. After treatment, both groups had lower CD8＋ than before treatment, and higher CD4＋ than before treatment. The observation group had lower CD8＋ than the control group, and higher CD4＋ than the control group. Their difference was statistically significant（P〈0.05）. Both groups had no obvious adverse reactions. Conclusion Montelukast can improve the therapeutic effect of asthma, and its mechanism may be related to reducing the level of inflammatory factors and improving the immune function.